Back to results
US 2026/0062467 A1Published application
Single-chain solanezumab antibody-transferrin fusion protein for enhanced efficacy and indications
AssigneeRNA Therapeutics, Inc.
InventorsMatthias Magoola, Sarfaraz K. Niazi
Life of this patent
Estimating the term…
Abstract
The efficacy and indication of solanezumab do not depend on the Fc region and are subject to transit across cell walls. They can be expanded by using their scFvs conjugated with N-methyl lobe of transferrin protein connected with an environment-sensitive cleavable linker to prevent exocytosis of the scFv yielding high exposure inside body cells such as in the brain, eye, and cancer cells that overexpress transferrin receptors.
Claims6
A fusion protein comprising a single chain variable fragment (scFv) of solanezumab antibody, conjugated with an N-terminal lobe of transferrin protein (PDB:
- 1a8e;
- 22-350 gene PRO1400, TF) using an environment-sensitive cleavable linker or linkers.
Dependencies are inferred from the claim text.